1-[5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-2,3-二氢-1H-吲哚-1-基]乙酮 | 937591-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-[5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-2,3-二氢-1H-吲哚-1-基]乙酮
• 英文名称: 1-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-indol-1-yl]ethanone
• 英文别名: 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-1-yl)-ethan-1-one；1-acetyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline；1-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-YL)indolin-1-YL)ethanone；1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydroindol-1-yl]ethanone
• CAS: 937591-32-7
• 化学式: C₁₆H₂₂BNO₃
• 分子量: 287.167
• InChiKey: UXKBEEFKAJIQLK-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.89
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-[5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-2,3-二氢-1H-吲哚-1-基]乙酮 在 sodium tetrahydroborate 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 甲醇 、 乙二醇二甲醚 、 水 为溶剂， 反应 1.0h， 生成 1-[5-(1-acetyl-2,3-dihydro-1H-indol-5-yl)pyridin-3-yl]ethanol
  参考文献：
  名称：

  Novel Pyridyl- or Isoquinolinyl-Substituted Indolines and Indoles as Potent and Selective Aldosterone Synthase Inhibitors

  摘要：

  Pathologically, high levels of aldosterone are associated with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial fibrosis. The inhibition of aldosterone synthase (CYP11B2) to reduce aldosterone levels has been proposed as a promising treatment for diseases related to CYP11B2 because it is the crucial enzyme in the biosynthesis of aldosterone. A series of novel pyridyl- or isoquinolinyl-substituted indolines and indoles was designed via a ligand-based approach. The synthesized compounds were tested and found to be strong CYP11B2 inhibitors. The most potent ones showed IC50 values of less than 3 nM, being similarly potent as fadrozole and LCI699. Among them, compounds 14 and 23 showed good selectivity over the highly homologous CYP11B1, with selectivity factors (SF = IC50 CYP11B1/IC50 CYP11B2) around 170; thus, they are superior to fadrozole and LCI699 (SFs < 15). These potent CYP11B2 inhibitors exhibited no inhibition (IC50 > 50 μM) of a panel of hepatic CYP enzymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 and the crucial steroidogenic enzymes, CYP17 and CYP19. Because of these advantageous profiles, compounds 14 and 23 are considered to be candidates for further in vivo evaluation.

  DOI：

  10.1021/jm500140c
• 作为产物：
  描述：

  1-乙酰基-5-氨基二氢吲哚 在 bis(1,5-cyclooctadiene)nickel (0) 、 甲酸 、 potassium tert-butylate 、 sodium cyanoborohydride 、 1,3-二环己基氯化咪唑 作用下， 以 甲醇 、 乙二醇乙醚 、 甲苯 为溶剂， 反应 40.0h， 生成 1-[5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-2,3-二氢-1H-吲哚-1-基]乙酮
  参考文献：
  名称：

  Nickel-Catalyzed Borylation of Aryl- and Benzyltrimethylammonium Salts via C–N Bond Cleavage

  摘要：

  By developing a mild Ni-catalyzed system, a method for direct borylation of sp(2) and sp(3) C-N bonds has been established. The key to this hightly efficient C-N bond borylative cleavage depends on the appropriate choice of the nickel catalyst Ni(COD)(2), ICy center dot HCl as a ligand, and the use of 2-ethoxyethanol as the cosolvent. This transformation shows good functional group compatibility and can serve as powerful synthetic tool for gram-scale synthesis and late-stage C-N borylation of complex compounds.

  DOI：

  10.1021/acs.joc.5b02557

文献信息

• [EN] N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES N-SUBSTITUÉS À TITRE D'INHIBITEURS DE KINASES
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014125410A1

  公开（公告）日：2014-08-21

  The present invention provides N-substituted novel heterocyclic derivatives of formula (I) as protein kinase inhibitors, in which R1, R2 and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的N-取代新异环衍生物作为蛋白激酶抑制剂，其中R1、R2和'n'的含义与规范中给出的含义相同，并且其药学上可接受的盐在治疗和预防疾病或紊乱方面具有用处，特别是它们在抑制激酶酶有优势的疾病或紊乱中的用途，更特别是BTK酶。本发明还提供了合成和给予激酶抑制剂化合物的方法。本发明还提供了包含至少一种激酶抑制剂化合物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia
  申请人：Berg Stefan

  公开号：US20090233930A9

  公开（公告）日：2009-09-17

  This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有以下结构式I的新化合物，以及它们的药学上可接受的盐、组合物和使用方法。这些新化合物提供了治疗或预防认知障碍、阿尔茨海默病、神经退行性和痴呆症的方法。
• Nickel-Catalyzed Borylation of Aryl- and Benzyltrimethylammonium Salts via C–N Bond Cleavage
  作者：Jiefeng Hu、Heqing Sun、Wangshui Cai、Xinghui Pu、Yemin Zhang、Zhuangzhi Shi

  DOI：10.1021/acs.joc.5b02557

  日期：2016.1.4

  By developing a mild Ni-catalyzed system, a method for direct borylation of sp(2) and sp(3) C-N bonds has been established. The key to this hightly efficient C-N bond borylative cleavage depends on the appropriate choice of the nickel catalyst Ni(COD)(2), ICy center dot HCl as a ligand, and the use of 2-ethoxyethanol as the cosolvent. This transformation shows good functional group compatibility and can serve as powerful synthetic tool for gram-scale synthesis and late-stage C-N borylation of complex compounds.
• Novel Pyridyl- or Isoquinolinyl-Substituted Indolines and Indoles as Potent and Selective Aldosterone Synthase Inhibitors
  作者：Lina Yin、Qingzhong Hu、Juliette Emmerich、Michael Man-Chu Lo、Edward Metzger、Amjad Ali、Rolf W. Hartmann

  DOI：10.1021/jm500140c

  日期：2014.6.26

  Pathologically, high levels of aldosterone are associated with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial fibrosis. The inhibition of aldosterone synthase (CYP11B2) to reduce aldosterone levels has been proposed as a promising treatment for diseases related to CYP11B2 because it is the crucial enzyme in the biosynthesis of aldosterone. A series of novel pyridyl- or isoquinolinyl-substituted indolines and indoles was designed via a ligand-based approach. The synthesized compounds were tested and found to be strong CYP11B2 inhibitors. The most potent ones showed IC50 values of less than 3 nM, being similarly potent as fadrozole and LCI699. Among them, compounds 14 and 23 showed good selectivity over the highly homologous CYP11B1, with selectivity factors (SF = IC50 CYP11B1/IC50 CYP11B2) around 170; thus, they are superior to fadrozole and LCI699 (SFs < 15). These potent CYP11B2 inhibitors exhibited no inhibition (IC50 > 50 μM) of a panel of hepatic CYP enzymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 and the crucial steroidogenic enzymes, CYP17 and CYP19. Because of these advantageous profiles, compounds 14 and 23 are considered to be candidates for further in vivo evaluation.